Results 191 to 200 of about 54,075 (219)

Pertuzumab/trastuzumab/trastuzumab-emtansine

Reactions Weekly, 2018
openaire   +1 more source

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort

Lancet, The, 2010
Luca Gianni, Vladimir Semiglazov, Alexey Manikhas   +2 more
exaly  

11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial

Lancet, The, 2017
David A Cameron, Evandro de Azambuja, Michael Untch   +2 more
exaly  

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer

New England Journal of Medicine, 2020
Kohei Shitara, Yung-Jue Bang, Satoru Iwasa   +2 more
exaly  

Trastuzumab

Reactions Weekly, 2013
openaire   +2 more sources

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial

Lancet, The, 2007
Ian Smith, Andrea Feyereislova, Mitch Dowsett   +2 more
exaly  

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer

New England Journal of Medicine, 2020
Shanu Modi, Cristina Saura, Toshinari Yamashita   +2 more
exaly  

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial

Lancet, The, 2013
Evandro de Azambuja, Christian Jackisch, David A Cameron   +2 more
exaly  

Trastuzumab

Reactions Weekly, 2012
openaire   +2 more sources

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

Lancet, The, 2019
Xavier Pivot, Jean-Yves Pierga, Thomas Bachelot   +2 more
exaly